GLP-1RAs and SGLT2i Combo Have better Outcomes in elderly with T2DM
Written By : MD Bureau
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2021-03-31 03:15 GMT | Update On 2021-03-31 03:15 GMT
Advertisement
Most patients with type 2 diabetes will eventually require a combination of at least two antidiabetic agents with different mechanisms of action to achieve glycaemic control. In a recent study, researchers have reported that in patients ≥65 years, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduced atherosclerotic outcomes and sodium-glucose co-transporter-2 inhibitors (SGLT2is) inhibitors reduced heart failure and renal outcomes. The study findings will be published in the journal DIABETES RESEARCH AND CLINICAL PRACTICE on April 01, 2021.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.